Clinical Trials
-
Principal Investigator:
Magdalena E Sobieszczyk, MD, MPHWe want to assess the baseline and cumulative seroprevalence of SARS-CoV-2 using serological and molecular assays. We will also administer a survey. Findings from this study will inform; 1) our understanding of changing epidemiology of COVID-19; 2) use of serological assays and testing algorithms, and 3) approaches to managing psychosocial stress in the community. -
Principal Investigator:
Magdalena E Sobieszczyk, MD, MPHClostridioides difficile (C. difficile) is a bacterium (germ) that can spread from one person to another causing severe diarrhea (watery poop) that at its worst can lead to death. Pfizer has been studying an investigational vaccine to prevent diarrhea caused by C. difficile. To be part of this study you must be 65 years old or older and have one or more of the risk factors for getting C. difficile diarrhea. Some of these risk factors are one (1) hospitalization for two (2) nights or longer; at least two (2) emergency room visits or at least ten (10) outpatient visits in the last 12 months;... -
Principal Investigator:
Michael T Yin, MDWe are seeking volunteers who have been diagnosed with COVID-19 by a healthcare provider or by lab testing. We are also looking for volunteers who have never tested positive for COVID-19 and have not received a COVID-19 vaccine. The study, also known as C-PIC, will be looking at antibody levels and how long the virus remains in the body. We are also studying the long-term complications that can occur after recovery from an acute COVID-19 infection, commonly referred to as long-COVID, long haul COVID, and post-acute sequelae of SARS-CoV-2 (PASC). At each visit, you will be asked to complete a... -
Principal Investigator:
Marcus Rebello Pereira, MD, MPHThis purpose of this study is to understand the interaction between two different medications, tacrolimus and Paxlovid (nirmatrelvir/ritonavir), in patients who have had a kidney transplant and are being treated by their doctor for COVID-19 infection. Tacrolimus is an oral medication that is used standardly in kidney transplant recipients to prevent rejection of the transplanted kidney. Paxlovid is an oral medication that is used to treat COVID-19 infection. Both medications are being prescribed by the patient's provider as part of their routine care. Participants will be asked to use a... -
Principal Investigator:
Magdalena E Sobieszczyk, MD, MPHWe are looking for individuals 18 to 65 years old who are interested in learning more about HIV prevention and biomedical research studies. We will ask you to complete a brief questionnaire to find out if we can schedule you for a one-on-one, 1.5-hour education visit to learn about the research we do. The education visit will help you decide if you want to participate in one of our studies. You will be compensated for the visit. Your responses to this questionnaire will be kept strictly confidential. -
Principal Investigator:
Magdalena E Sobieszczyk, MD, MPHWe are looking for individuals 18 to 65 years old who are interested in learning more about HIV prevention and biomedical research studies. We will ask you to complete a brief questionnaire to find out if we can schedule you for a one-on-one, 1.5-hour education visit to learn about the research we do. The education visit will help you decide if you want to participate in one of our studies. You will be compensated for the visit. Your responses to this questionnaire will be kept strictly confidential. -
Principal Investigator:
Marcus Rebello Pereira, MD, MPHThe primary objective is to determine whether using hearts from HIV+ donors for HIV+ recipients is safe with regard to major transplant-related and HIV-related complications. The primary outcome is patient survival at one year. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC). -
Principal Investigator:
Marcus Rebello Pereira, MD, MPHThe primary objective is to determine whether using hearts from HIV+ donors for HIV+ recipients is safe with regard to major transplant-related and HIV-related complications. The primary outcome is patient survival at one year. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC). -
Principal Investigator:
Marcus Rebello Pereira, MD, MPHThis research is being done to better understand rejection in transplant recipients with HIV who receive kidneys from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC). -
Principal Investigator:
Marcus Rebello Pereira, MD, MPHThe primary objective is to evaluate long-term outcomes in transplant recipients with HIV who receive livers from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).